Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

Lancet
Rodney DawsonCarl M Mendel

Abstract

New antituberculosis regimens are urgently needed to shorten tuberculosis treatment. Following on from favourable assessment in a 2 week study, we investigated a novel regimen for efficacy and safety in drug-susceptible and multidrug-resistant (MDR) tuberculosis during the first 8 weeks of treatment. We did this phase 2b study of bactericidal activity--defined as the decrease in colony forming units (CFUs) of Mycobacterium tuberculosis in the sputum of patients with microscopy smear-positive pulmonary tuberculosis-at eight sites in South Africa and Tanzania. We enrolled treatment-naive patients with drug-susceptible, pulmonary tuberculosis, who were randomly assigned by computer-generated sequences to receive either 8 weeks of moxifloxacin, 100 mg pretomanid (formerly known as PA-824), and pyrazinamide (MPa100Z regimen); moxifloxacin, 200 mg pretomanid, and pyrazinamide (MPa200Z regimen); or the current standard care for drug-susceptible pulmonary tuberculosis, isoniazid, rifampicin, PZA, and ethambutol (HRZE regimen). A group of patients with MDR tuberculosis received MPa200Z (DRMPa200Z group). The primary outcome was bactericidal activity measured by the mean daily rate of reduction in M tuberculosis CFUs per mL overnight spu...Continue Reading

References

May 6, 2006·American Journal of Respiratory and Critical Care Medicine·William J BurmanRichard E Chaisson
Aug 31, 2006·Antimicrobial Agents and Chemotherapy·Geraint R DaviesLeon J Aarons
Jun 5, 2007·Bulletin of the World Health Organization·Yvo Nuyens
May 2, 2009·American Journal of Respiratory and Critical Care Medicine·Susan E DormanUNKNOWN Tuberculosis Trials Consortium
May 26, 2010·Antimicrobial Agents and Chemotherapy·Andreas H DiaconMelvin K Spigelman
Sep 8, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A H DiaconP R Donald
Oct 13, 2012·The European Respiratory Journal·G B MiglioriUNKNOWN “The Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB”
Feb 22, 2013·The New England Journal of Medicine·Alimuddin ZumlaC Fordham von Reyn
Aug 21, 2013·Primary Care·Wanda Cruz-Knight, Lyla Blake-Gumbs
Mar 29, 2014·The Lancet Infectious Diseases·Alimuddin I ZumlaAndrew J Nunn
Sep 10, 2014·The New England Journal of Medicine·Stephen H GillespieUNKNOWN REMoxTB Consortium

❮ Previous
Next ❯

Citations

Jan 23, 2016·Proceedings of the National Academy of Sciences of the United States of America·Tim R BlowerJames M Berger
Feb 18, 2016·Transactions of the Royal Society of Tropical Medicine and Hygiene·Derek J Sloan, Joseph M Lewis
Aug 22, 2015·Expert Opinion on Pharmacotherapy·Susanna EspositoFrancesco Blasi
Nov 19, 2015·Expert Opinion on Investigational Drugs·Yong-Soo Kwon, Won-Jung Koh
Feb 10, 2016·Der Internist·R Otto-KnappT Bauer
Jul 5, 2015·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Gerard R Alexander, Bruce Biccard
Oct 21, 2015·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Ping XuJunhua Xu
Nov 2, 2015·Advances in Medical Sciences·Moses NjireTianyu Zhang
Dec 15, 2015·Journal of Molecular Biology·Kemin TanYuk-Ching Tse-Dinh
Jan 21, 2016·Der Internist·T Schaberg
Jan 16, 2016·The Korean Journal of Internal Medicine·Wing Wai Yew, Won-Jung Koh
Jul 30, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alimuddin ZumlaUNKNOWN Host-Directed Therapies Network (HDT-NET) Consortium
Mar 10, 2016·Expert Review of Respiratory Medicine·Ignacio MonederoAdrian Sanchez Montalva
Sep 27, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marco SchitoAlimuddin Zumla
Jun 23, 2015·Clinical Pharmacology and Therapeutics·H S SchaafP R Donald
Apr 14, 2016·Future Microbiology·Juan Carlos Palomino, Anandi Martin
May 27, 2015·The Journal of Infectious Diseases·Tawanda GumboEric Nuermberger
May 18, 2016·Bioorganic & Medicinal Chemistry Letters·Lokesh PulipatiSrinivas Kantevari
May 22, 2016·Infectious Disease Clinics of North America·Sebastian G KurzCharles M Bark
Jun 11, 2016·Future Medicinal Chemistry·Yuk-Ching Tse-Dinh
Jun 9, 2016·Expert Review of Respiratory Medicine·Alberto MatteelliGiovanni Battista Migliori
Jul 28, 2016·Expert Opinion on Pharmacotherapy·Michael Lauzardo, Charles A Peloquin
Apr 3, 2016·The Lancet Infectious Diseases·Robert S WallisAlimuddin Zumla
Sep 15, 2016·The New England Journal of Medicine·Matteo ZignolMario C Raviglione
Oct 7, 2016·AIDS Research and Therapy·Narendran GopalanSrikanth Tripathy
Nov 26, 2016·Bioscience, Biotechnology, and Biochemistry·Masayuki Igarashi
Dec 23, 2016·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Emily A KendallDavid W Dowdy
May 13, 2017·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Ping XuJunhua Xu
Jun 1, 2017·Expert Review of Respiratory Medicine·Ignacio MonederoAdrián Sánchez-Montalvá
Jun 1, 2017·Proceedings of the National Academy of Sciences of the United States of America·Kohta SaitoCarl F Nathan
Jun 28, 2017·Journal of Chemotherapy·Lucie BarthodPatrice Vanelle
Mar 28, 2018·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Muhammad Tahir KhanMuhammad Tanvir Afzal
Apr 25, 2018·Nature Reviews. Microbiology·Sabine EhrtKyu Y Rhee
Dec 12, 2017·Expert Opinion on Drug Metabolism & Toxicology·Ilaria MottaStefano Bonora

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Related Papers

American Journal of Respiratory and Critical Care Medicine
Andreas H DiaconCarl M Mendel
Antimicrobial Agents and Chemotherapy
Andreas H DiaconMelvin Spigelman
© 2021 Meta ULC. All rights reserved